Breast cancer is the second deadliest form of cancer in women in the United States. The disease’s strong resistance to known traditional treatment options have created a need for better solutions. Cannabidiol (CBD) is a natural product with validated anti-cancer properties. It induces toxicity in human glioma, leukemia, and breast cancer cells (in vitro) and inhibits the metastasis of breast cancer cells.
The Molecular Cancer Therapeutics medical journal explored a study into the mechanisms by which CBD carries out various processes in breast cancer cells lines. "Antineoplastic" properties are those that can prevent the growth and spread of tumors or malignant cells. CBD is considered an antineoplastic agent and has properties that fight against tumor cells.
"Autophagy" is the natural, regulated, destructive mechanism of the cell that disassembles unnecessary or dysfunctional components. The study revealed an interplay between cell death and autophagy in CBD-treated breast cancer cells. This points to future use of CBD as an antineoplastic agent.
The study showed that CBD induced the death of breast cancer cells. Although CBD decreased the viability of both cancerous and non-cancerous cell lines, significantly more non-cancerous cells survived CBD treatment compared to breast cancer cells. This suggests that CBD may preferentially kill cancer cells versus normal cells.
Cannabidiol has shown the ability to facilitate cell death in cervical cancer cells and breast cancer cells as well. Quicker advancements are underway with waves of CBD research on the horizon. Cost-effectiveness and the non-psychoactive effects associated with CBD administration make it a perfect alternative to traditional treatments. Time continues to reveal the potential use of CBD as a developing solution for targeting additional variations of cancer cells.